Nasdaq GlobeNewswire

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results

– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance –

NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802

 

AMES, Iowa, July 27, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced first patient dosed in the Phase 1 study of NLG802, a novel prodrug of indoximod.  NLG802 is an investigational agent targeting the IDO pathway and represents an important step in the company’s strategic planning and intellectual property (IP) management.

MacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call

ROCKVILLE, MD, July 26, 2017 (GLOBE NEWSWIRE) --

Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast

 

SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2017 financial results after the market closes on Thursday, August 3, 2017 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast.  During the conference call, the Company will review financial results and discuss other business matters.

Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report second quarter 2017 financial results and provide a corporate update after the close of U.S. financial markets on Wednesday, August 2, 2017. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 2, 2017.

Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call

SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ second quarter 2017 financial results will be released on Wednesday, August 2, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Wednesday, August 2, 2017 at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial

AXS-06 is an oral, rapidly-absorbed, once-daily, non-opioid, COX-2 preferential pain therapeutic with a gastroprotectant

Kraig Biocraft Laboratories to Open New Vietnam Headquarters in Quang Nam Province

 

ANN ARBOR, Mich., July 24, 2017 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that it has identified and selected the location for its operational headquarters in Vietnam.  Located in the heart of Quang Nam province, this area provides a vast supply of skilled workers, close proximity to mulberry fields, and easy access to international air and sea ports.  This location was selected based on a series of productive and successful meetings between representatives of Kraig Labs, provincial leaders, and local silk experts.  The Company plans for this facility to be used for the first shipment of the Company’s transgenic silkworm technology into Vietnam. 

Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs

 

  • Phase 2 data in older adults (E205) demonstrate adjuvants and 2-dose regimens significantly increase the magnitude, duration and quality of the RSV F Vaccine immune response
     
  • New data demonstrate that Novavax’ construct is a stable prefusogenic RSV F antigen, distinctive from other candidates, that elicits potent neutralizing antibody responses to multiple key epitopes
     
  • Path forward for a Phase 2 efficacy trial in 2018 based on signal in COPD population identified in prior older adult clinical trials
     
  • Phase 3 Prepare™ trial accelerating and now includes 80 sites across 11 countries allowing continuous enrollment across global seasons      

BioCryst to Announce Second Quarter 2017 Financial Results on August 7

RESEARCH TRIANGLE PARK, N.C., July 24, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2017 financial results will be reported on Monday, August 7, 2017.

Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

 

BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, today announced the closing of an underwritten public offering of units for gross proceeds of $15.2 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Cyclacel. Existing and new investors participated in the offering.

VANC Pharmaceuticals Announces Non Brokered Private Placement

 

VANCOUVER, British Columbia, July 20, 2017 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC” or the “Company”) (TSXV:VANC) (OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets, is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.15 per unit (the “Units”) for gross proceeds of up to $1,500,000 (the “Offering”). 

Lentigen Technology Inc., a Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma, Inc.

  • Lentigen Technology Inc., a leading provider of GMP lentiviral vectors, will further advance Living Pharma’s personalized chimeric antigen receptor (CAR) T-cell therapies targeting various cancers
  • Co-founded by an award-winning University of Maryland, Baltimore (UMB), immunotherapy researcher, Living Pharma is the first UMB New Ventures Initiative start-up to execute a successful exit

Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi

LAKE FOREST, Ill., July 19, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, announced that its shareholders, at a special meeting held earlier today, have overwhelmingly voted to approve the previously announced merger agreement providing for the acquisition of Akorn by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA (FWB:FRE).

Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering

 

BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, today announced the pricing of an underwritten public offering of units for gross proceeds of $13.2 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Cyclacel.

Animal Healthcare Market worth over $36 billion by 2024: Global Market Insights, Inc.

Ocean View, Delaware, July 19, 2017 (GLOBE NEWSWIRE) --

Organovo Announces Release Date for Fiscal First-Quarter 2018 Financial Results

 

SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Wednesday, August 9, 2017 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal first-quarter 2018 financial results.  In advance of the call on August 9, 2017, Organovo will issue its fiscal first-quarter 2018 earnings press release, which will be available at http://www.organovo.com.  To participate in the teleconference, callers can dial the following numbers:

RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017

 

TEL-AVIV, Israel and RALEIGH, N.C., July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it will report its second quarter 2017 financial results on Tuesday, July 25, 2017.

Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017

ROCKVILLE, MD, July 17, 2017 (GLOBE NEWSWIRE) --

Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation

First patient enrolled in the ADVANCE-1 study